Two directors resign from Apogee Therapeutics (NASDAQ: APGE) board, shrinking it to seven
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.
Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective resignation date: May 11, 2026
Board size before resignations: nine directors
Board size after resignations: seven directors
+1 more
4 metrics
Effective resignation date
May 11, 2026
Directors’ Board resignations become effective
Board size before resignations
nine directors
Board composition prior to May 11, 2026
Board size after resignations
seven directors
Board composition effective May 11, 2026
Notice date
April 21, 2026
Date both directors notified the Board
Key Terms
Board of Directors, Emerging growth company, Item 5.02, Securities Exchange Act of 1934
4 terms
Board of Directors financial
"each notified the Board of Directors (the “Board”) of Apogee Therapeutics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"
Securities Exchange Act of 1934 regulatory
"Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report"
FAQ
What did Apogee Therapeutics (APGE) disclose in this 8-K filing?
Apogee Therapeutics disclosed that directors Andrew Gottesdiener, M.D. and Peter Harwin plan to resign from the Board effective May 11, 2026. The company also stated that the resignations are not due to any disagreement regarding its operations, policies, or practices.
When will the Apogee Therapeutics (APGE) director resignations become effective?
The resignations of Andrew Gottesdiener, M.D. and Peter Harwin from Apogee Therapeutics’ Board will become effective on May 11, 2026. Both directors notified the Board of their intentions on April 21, 2026, providing several weeks of transition time before their departures.
Why are the Apogee Therapeutics (APGE) directors resigning from the Board?
Apogee Therapeutics stated that the resignations of Andrew Gottesdiener, M.D. and Peter Harwin are not the result of any disagreement with the company. This includes no disagreement on operations, policies, or practices, suggesting routine or personal reasons rather than governance conflicts.
How will Apogee Therapeutics’ (APGE) Board size change after the resignations?
After the resignations of Andrew Gottesdiener, M.D. and Peter Harwin become effective on May 11, 2026, Apogee Therapeutics’ Board will shrink from nine directors to seven. The filing specifies this reduction in Board size as part of the post-resignation governance structure.
Who signed the Apogee Therapeutics (APGE) 8-K reporting these Board changes?
The 8-K reporting the director resignations at Apogee Therapeutics was signed by Michael Henderson, M.D., the company’s Chief Executive Officer. His signature indicates the company’s formal authorization and confirmation of the disclosed Board changes and related details.